BioSpace News Archive

Bio-Path Holdings, Inc., (NASDAQ: BPTH), today presented a poster highlighting preclinical BP1003 data at the 2022 American Association for Cancer Research (AACR) Annual Meeting.

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced preclinical data from six poster presentations at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisiana.

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it has commenced an underwritten public offering of common shares.

AbCellera (Nasdaq: ABCL) will announce its first quarter 2022 financial results on Tuesday, May 10, 2022, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

Medical devices are utilized to complete tasks, medicines and finding, and differ in light of intricacy and applications.

Gritstone bio, Inc. delivered three presentations further supporting the potential of its novel vaccine development capabilities and delivery platforms to develop transformational therapeutic cancer vaccines at the 2022 American Association for Cancer Research Annual Meeting.

Endo International plc (NASDAQ: ENDP) will announce its first–quarter 2022 financial results on May 5, 2022 and members of its senior management team will host a conference call and webcast on May 6, 2022 at 7:30am ET before the U.S. financial markets open.

Alpine Immune Sciences, Inc. announced the oral presentation of results from the dose-escalation portion of NEON-1, a first-in-human, dose-escalation and expansion study of davoceticept monotherapy in participants with advanced malignancies, at the 2022 Annual Meeting of the American Association for Cancer Research.

AffaMed Therapeutics, a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, announced that DEXTENZA has been approved in Macau, China for the treatment of ocular inflammation and pain following ophthalmic surgery.

Adam Clarke, CEO and Principal Consultant of Stratus commented, “The projects that Nirvana Life Sciences are advancing represent the evolution of modern medicine.